Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Barinthus Biotherapeutics

    NASDAQ: BRNS · Real-Time Price · USD
    0.91
    0.01 (0.74%)
    At close: Jun 16, 2025, 3:59 PM
    0.93
    1.96%
    After-hours: Jun 16, 2025, 06:14 PM EDT

    Barinthus Biotherapeutics Statistics

    Share Statistics

    Barinthus Biotherapeutics has 40.34M shares outstanding. The number of shares has increased by 1.51% in one year.

    Shares Outstanding

    n/a
    		 40.34M

    Shares Change (YoY)

    n/a
    		 1.51%

    Shares Change (QoQ)

    n/a
    		 0%

    Owned by Institutions (%)

    n/a
    		 n/a

    Shares Floating

    n/a
    		 36.92M

    Failed to Deliver (FTD) Shares

    n/a
    		 706

    FTD / Avg. Volume

    n/a
    		 2.06%

    Short Selling Information

    The latest short interest is 39.29K, so 0.1% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 39.29K

    Short % of Shares Out

    n/a
    		 0.1%

    Short % of Float

    n/a
    		 0.15%

    Short Ratio (days to cover)

    n/a
    		 1

    Valuation Ratios

    The PE ratio is -0.78 and the forward PE ratio is -0.68. Barinthus Biotherapeutics's PEG ratio is 0.04.

    PE Ratio

    n/a
    		 -0.78

    Forward PE

    n/a
    		 -0.68

    PS Ratio

    n/a
    		 3.18

    Forward PS

    n/a
    		 2.3

    PB Ratio

    n/a
    		 0.37

    P/FCF Ratio

    n/a
    		 -1.6

    PEG Ratio

    n/a
    		 0.04
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Barinthus Biotherapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 8.03, with a Debt / Equity ratio of 0.09.

    Current Ratio

    n/a
    		 8.03

    Quick Ratio

    n/a
    		 8.03

    Debt / Equity

    n/a
    		 0.09

    Debt / EBITDA

    n/a
    		 -0.22

    Debt / FCF

    n/a
    		 -0.4

    Interest Coverage

    n/a
    		 -1282.45

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $142,561.9

    Profits Per Employee

    n/a
    		 $-581,657.14

    Employee Count

    n/a
    		 105

    Asset Turnover

    n/a
    		 0.09

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 -44K

    Effective Tax Rate

    n/a
    		 0.07%

    Stock Price Statistics

    The stock price has increased by -46.15% in the last 52 weeks. The beta is -0.77, so Barinthus Biotherapeutics's price volatility has been lower than the market average.

    Beta

    n/a
    		 -0.77

    52-Week Price Change

    n/a
    		 -46.15%

    50-Day Moving Average

    n/a
    		 0.88

    200-Day Moving Average

    n/a
    		 1.05

    Relative Strength Index (RSI)

    n/a
    		 47.51

    Average Volume (20 Days)

    n/a
    		 34,230

    Income Statement

    In the last 12 months, Barinthus Biotherapeutics had revenue of 14.97M and earned -61.07M in profits. Earnings per share was -1.55.

    Revenue

    n/a
    		 14.97M

    Gross Profit

    n/a
    		 9.17M

    Operating Income

    n/a
    		 -67.97M

    Net Income

    n/a
    		 -61.07M

    EBITDA

    n/a
    		 -55.37M

    EBIT

    n/a
    		 -61.17M

    Earnings Per Share (EPS)

    n/a
    		 -1.55
    Full Income Statement

    Balance Sheet

    The company has 110.66M in cash and 12.01M in debt, giving a net cash position of 98.66M.

    Cash & Cash Equivalents

    n/a
    		 110.66M

    Total Debt

    n/a
    		 12.01M

    Net Cash

    n/a
    		 98.66M

    Retained Earnings

    n/a
    		 -237.66M

    Total Assets

    n/a
    		 142M

    Working Capital

    n/a
    		 97.91M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -28.94M and capital expenditures -892K, giving a free cash flow of -29.83M.

    Operating Cash Flow

    n/a
    		 -28.94M

    Capital Expenditures

    n/a
    		 -892K

    Free Cash Flow

    n/a
    		 -29.83M

    FCF Per Share

    n/a
    		 -0.76
    Full Cash Flow Statement

    Margins

    Gross margin is 61.28%, with operating and profit margins of -454.07% and -408%.

    Gross Margin

    n/a
    		 61.28%

    Operating Margin

    n/a
    		 -454.07%

    Pretax Margin

    n/a
    		 -409.03%

    Profit Margin

    n/a
    		 -408%

    EBITDA Margin

    n/a
    		 -369.92%

    EBIT Margin

    n/a
    		 -454.07%

    FCF Margin

    n/a
    		 -199.29%

    Dividends & Yields

    BRNS does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for BRNS is $3, which is 229.7% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $3

    Price Target Difference

    n/a
    		 229.7%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 1
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -1.86

    Piotroski F-Score

    n/a
    		 3

    Add to Watchlist